European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis.
Herpes zoster (HZ, shingles) is a frequent medical condition which may severely impact the quality of life of affected patients. Different therapeutic approaches to treat acute HZ are available. The aim of this European project was the elaboration of a consensus-based guideline on the management of patients who present with HZ, considering different patient populations and different localizations. This interdisciplinary guideline aims at an improvement of the outcomes of the acute HZ management concerning disease duration, acute pain and quality of life of the affected patients and at a reduction of the incidence of postherpetic neuralgia and other complications. The guideline development followed a structured and predefined process, considering the quality criteria for guidelines development as suggested by the AGREE II instrument. The steering group was responsible for the planning and the organization of the guideline development process (Division of Evidence based Medicine, dEBM). The expert panel was nominated by virtue of clinical expertise and/or scientific experience and included experts from the fields of dermatology, virology/infectiology, ophthalmology, otolaryngology, neurology and anaesthesiology. Recommendations for clinical practice were formally consented during the consensus conference, explicitly considering different relevant aspects. The guideline was approved by the commissioning societies after an extensive internal and external review process. In this first part of the guideline, diagnostic means have been evaluated. The expert panel formally consented recommendations for the management of patients with (suspected) HZ, referring to the assessment of HZ patients, considering various specific clinical situations. Users of the guideline must carefully check whether the recommendations are appropriate for the context of intended application. In the setting of an international guideline, it is generally important to consider different national approaches and legal circumstances with regard to the regulatory approval, availability and reimbursement of diagnostic and therapeutic interventions.
Division of Evidence Based Medicine in Dermatology (dEBM), Department of Dermatology, Venereology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
R N
RN
Werner
Department of Dermatology, University Medical Center of Liège, Liège, Belgium.
A F
AF
Nikkels
Department of Dermatology and Venereology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia.
B
B
Marinović
Department of Anesthesiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
M
M
Schäfer
Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
M
M
Czarnecka-Operacz
Department of Otorhinolaryngology, The Medical School, University of Malta, Msida, Malta.
A M
AM
Agius
Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Z
Z
Bata-Csörgő
Division of Infection and Immunity, University College London, London, UK.
J
J
Breuer
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
G
G
Girolomoni
Department of Dermatology and Venerology, Universitätsklinik Rostock, Rostock, Germany.
G E
GE
Gross
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
S
S
Langan
Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
R
R
Lapid-Gortzak
Department of Otolaryngology, University Hospital Aintree NHS Foundation Trust, Liverpool, UK.
T H
TH
Lesser
Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
U
U
Pleyer
Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
J
J
Sellner
Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
G M
GM
Verjans
Department of Virology and Antiviral Therapy, Jena University Hospital, Jena, Germany.
P
P
Wutzler
Division of Evidence Based Medicine in Dermatology (dEBM), Department of Dermatology, Venereology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
C
C
Dressler
Division of Evidence Based Medicine in Dermatology (dEBM), Department of Dermatology, Venereology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
R
R
Erdmann
Division of Evidence Based Medicine in Dermatology (dEBM), Department of Dermatology, Venereology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
S
S
Rosumeck
Division of Evidence Based Medicine in Dermatology (dEBM), Department of Dermatology, Venereology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
A
A
Nast
D006801:Humans; D000914:Antibodies, Viral / Q000032:analysis / Q000235:genetics; D000956:Antigens, Viral / Q000032:analysis / Q000235:genetics; D002460:Cell Line; D005060:Europe; D006562:Herpes Zoster / Q000175:diagnosis / Q000503:physiopathology; D014645:Herpesvirus 3, Human / Q000235:genetics / Q000276:immunology; D016133:Polymerase Chain Reaction; D012307:Risk Factors; D012680:Sensitivity and Specificity; D012955:Societies, Medical
D000914:Antibodies, Viral; D000956:Antigens, Viral